Retrospective Cohort Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jun 14, 2016; 22(22): 5237-5245
Published online Jun 14, 2016. doi: 10.3748/wjg.v22.i22.5237
Table 1 Clinicopathological characteristic of patients with obstructive colorectal cancer n (%)
VariableCategoryn = 234
GenderMale141(60.3)
Female93 (39.7)
Age (yr)171 (35-96)
ASAI70 (30)
II128 (54.7)
III36 (15.3)
Location of tumorCecum10 (4.3)
Ascending colon33 (14.1)
Transverse colon33 (14.1)
Descending colon36 (15.4)
Sigmoid colon95 (40.6)
Rectum15 (10.5)
Decompression+183 (78.2)
-51 (21.8)
CEA (mg/dL) 14.9 (0.3-2470)
Serum albumin13.4 (1.4-4.9)
Tumor size(mm)48 (10-140)
Depth of tumorpT3109 (46.6)
pT4a93 (39.7)
pT4b32 (13.7)
Lymph node involvementN0113 (48.3)
N190 (38.5)
N231 (13.2)
R0 resection+219 (93.6)
-15 (6.4)
Adjuvant chemotherapy+91 (38.9)
-143 (61.1)
Table 2 Patterns of recurrence following colorectal resection of obstructive colorectal cancer (n = 71)
Site of recurrencen (%)
Liver27 (11.5)
Lung22 (9.4)
Peritoneal dissemination21 (9.0)
Local recurrence9 (3.8)
Lymph node6 (2.6)
Anastomosis3 (1.3)
Abdominal wall2 (0.9)
Pleural dissemination2 (0.9)
Table 3 Result of the univariate and multivariate analysis of risk factors for recurrence
FactornUnivariate analysis
Multivariate analysis
3-yr RFS5-yr RFSP valueHR (95%CI)P value
GenderM14159.2%47.6%0.409
F9366.8%54.7%
Age (yr)≥ 759655.0%42.4%0.0111.228 (0.659-2.290)0.518
< 7513867.3%55.9%
ASA-PS17175.7%64.8%0.0172.234 (1.101-4.535)0.026
2-316356.6%44.6%
BMI (kg/m2)≥ 252866.0%49.7%0.951
< 2519362.7%52.7%
Serum albumin (g/dL) ≤ 4.017254.9%41.3%0.0012.967 (1.342-6.560)0.007
> 4.04879.7%73.1%
CEA (mg/dL)≥ 5.010252.4%44.8%0.052
< 5.011374.1%54.2%
Decompression+18362.9%50.7%0.572
-5160.5%50.4%
Location of tumorRight side6962.5%55.5%0.738
Left side16562.1%48.7%
Tumor size (mm)≥ 509961.0%48.8%0.384
< 5012163.9%54.1%
Differentiation of tumortub1,tub222263.7%51.2%0.080
por, muc1236.7%36.7%
Depth of tumorT310873.5%64.7%0.0012.728 (1.467-5.072)0.002
T412653.0%38.7%
Intramural lymphatic invasion+15761.4%53.2%0.600
-7364.4%45.2%
Intramural vascular invasion+16460.3%49.3%0.683
-7068.1%57.4%
Lymph node involvement+12065.7%47.4%0.856
-11459.1%53.2%
Lymph node dissectionD0,D13144.3%44.3%0.067
D2,D319964.7%50.8%
No. of lymph nodes harvested< 127354.8%44.5%0.085
≥ 1215166.4%52.5%
Postoperative complication+7857.3%44.7%0.071
(≥ Grade 2)-15664.7%53.5%
Anastomotic leakage+1871.1%56.9%0.562
-19161.7%50.0%
CurabilityR021966.4%54.8%< 0.0016.555 (1.344-31.970)0.020
R1157.6%0.0%
Adjuvant chemotherapy+9166.2%55.6%0.069
-14359.8%47.2%
Table 4 Result of the univariate and multivariate analysis of prognostic factors for cancer-specific survival
FactornUnivariate analysis
Multivariate analysis
3-yr CSS5-yr CSSP valueHR(95%CI)P value
GenderM14188.3%80.8%0.924
F9387.8%79.7%
Age (yr)≥ 759682.2%71.6%0.0271.464 (0.647-3.310)0.360
< 7513891.9%85.4%
ASA-PS17186.0%83.5%0.710
2-316389.0%78.7%
BMI (kg/m2)≥ 252892.0%85.8%0.389
< 2519387.3%80.0%
Serum albumin (g/dL) ≤ 4.017285.6%82.6%0.536
> 4.04887.7%76.2%
CEA (mg/dL)≥ 5.010286.7%80.0%0.715
< 5.011390.5%82.0%
Decompression+18388.4%81.7%0.514
-5187.1%74.8%
Location of tumorRight side6982.6%70.5%0.103
Left side16590.4%84.3%
Tumor size (mm)≥ 509984.1%76.9%0.291
< 5012190.4%85%
Differentiation of tumortub1, tub222289.9%82.5%0.0016.282 (1.584-24.909)0.009
por, muc1250.0%50.0%
Depth of tumorT310895.7%92.3%0.0013.458 (1.324-9.031)0.011
T412681.1%69.2%
Intramural lymphatic invasion+15790.8%82.7%0.449
-7386.9%79.4%
Intramural vascular invasion+16494.2%90.1%0.152
-7085.9%76.7%
Lymph node involvement+12092.5%82.9%0.332
-11484.0%77.7%
Lymph node dissectionD0, D13160.7%60.7%0.0140.958 (0.300-3.056)0.942
D2, D319990.4%83.0%
No. of lymph nodes harvested< 127383.3%78.3%0.314
≥ 1215191.1%81.0%
Postoperative complication+7885.9%75.6%0.644
(≥ Grade 2)-15689%82.5%
Anastomotic leakage+18100%100%0.069
-19187.1%78.7%
CurabilityR021991.3%84.7%< 0.0016.162 (1.692-22.445)0.006
R11539.7%19.9%
Adjuvant chemotherapy+9187.7%81.8%0.800
-14388.8%79.4%